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Abstract 
Natural products remain an important source of new drugs, new drug 
leads and new chemical entities. The plant based drug discovery 
resulted mainly in the development of anticancer agents including 
plants (vincristine, vinblastine, etoposide, paclitaxel, camptothecin, 
topotecan and irinotecan), marine organisms (citarabine, aplidine and 
dolastatin 10) and micro-organisms (dactinomycin, bleomycin and 
doxorubicin). Beside this there is numerous agents identified from 
fruits and vegetables can used in anticancer therapy. The agents 
include curcumin (turmeric), resveratrol (red grapes, peanuts and 
berries), genistein (soybean), diallyl sulfide (allium), S-allyl cysteine 
(allium), allicin (garlic), lycopene (tomato), capsaicin (red chilli), 
diosgenin (fenugreek), 6-gingerol (ginger), ellagic acid 
(pomegranate), ursolic acid (apple, pears, prunes), silymarin (milk 
thistle), anethol (anise, camphor, and fennel), catechins (green tea), 
eugenol (cloves), indole-3-carbinol (cruciferous vegetables), 
limonene (citrus fruits), beta carotene (carrots), and dietary fiber. In 
this review active principle derived from natural products are 
offering a great opportunity to evaluate not only totally new 
chemical classes of anticancer agents, but also novel lead compound 
and potentially relevant mechanisms of action.  
Keywords: Cancer, vincristin, vinblastin, fruit, vegetables. 
 
Introduction 
Cancer continues to be one of the major causes 
of death worldwide and only modest progress 
has been made in reducing the morbidity and 
mortality of this disease [1]. Cancers may be 
caused in one of three ways, namely incorrect 
diet, genetic predisposition, and via the 
environment. As many as 95% of all cancers are 
caused by life style and may take as long as 20–
30 years to develop. Current estimates from the 
American Cancer Society and from the 
International Union Against Cancer indicate that 
12 million cases of cancer were diagnosed last 
year, with 7 million deaths worldwide; these 
numbers are expected to double by 2030 (27 
million cases with 17 million deaths) [2].  
According to a report of World Health 
Organization, more than 80% of world’s 
populations depend on traditional medicine for 
their primary health care needs [3,4]. Plants 
have a long history of use in the treatment of 
cancer and it is significant that over 60% of 
currently used anti-cancer agents are come from 
natural sources [5]. Naturally occurring drugs 
that are part of the war against cancer include 
vinca alkaloids (vincristine, vinblastine, 
vindesine, vinorelbine), taxanes (paclitaxel, 
docetaxel), podophyllotoxin and its derivative 
(etoposide, teniposide), camptothecin and its 
derivatives (topothecan, irinothecan), 
anthracyclines (doxorubicin, daunorubicin, 
epirubicin, idarubicin) and others. In fact, half 
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of all anti-cancer drugs approved internationally 
were either natural products or their derivatives 
and were developed on the basis of knowledge 
gained from small molecules or macromolecules 
that exist in nature [6,7]. In between 2001 and 
2005, 23 new drugs derived from natural 
products were introduced for the treatment of 
disorders such as bacterial and fungal infections, 
cancer, diabetes, dyslipidemia, atopic dermatitis, 
Alzheimer’s disease and genetic diseases such 
as tyrosinaemia and Gaucher disease out of 
these 4 drugs have been approved as anti cancer 
agents. The approved anti cancer agents in 2002 
doxorubicin, in 2002 estradiol, in 2004 
cholorophyll and l- aspartic acid and taxol 
nanoparticles in 2005 [8]. Three new drugs also 
introduced in 2007 originate from microbial 
sources for the treatment of cancer is marine 
alkaloid trabectedin, epothilone derivative 
ixabepilone and temsirolimus [9].  
 
Nature is an attractive source of new therapeutic 
candidate compounds as a tremendous chemical 
diversity is found in millions of species of 
plants, animals, marine organisms and 
microorganisms as potential anti-cancer agent 
[10,11]. In this present study the potential anti-
cancer agent from plants, marines, 
microorganisms and dietary (fruits, vegetables, 
and spices) sources with some recent 
advancement in the field of cancer research 
were discussed.  
 
Plants as source of anti-cancer agents:  
The history of plant as source of anti-cancer 
agents started in earnest in the 1950s with the 
discovery and development of the vinca 
alkaloids (vinblastine and vincristine) and the 
isolation of the cytotoxic podophyllotoxins. 
Vinca alkaloid was responsible for an increase 
in the cure rates for Hodgkin’s disease and some 
forms of leukemia [12]. Vincristine inhibits 
microtubule assembly, inducing tubulin self-
association into coiled spiral aggregates [13]. 
Etoposide is a epipodophyllotoxin, derived from 
the mandrake plant Podophyllum peltatum and 
the wild chervil Podophyllum emodi [14]. It has 
also significant activity against small-cell lung 
carcinoma [15]. Etoposide is a topoisomerase II 
inhibitor, stabilizing enzyme–DNA cleavable 
complexes leading to DNA breaks [16]. The 
taxanes paclitaxel and docetaxel has been show 
antitumor activity against breast, ovarian and 
other tumor types in the clinic trial. Paclitaxel 
stabilizes microtubules and leading to mitotic 
arrest [17]. In addition, the camptothecin 
derivatives irinotecan and topotecan, have 
shown significant antitumor activity against 
colorectal and ovarian cancer respectively 
[18,19]. These compounds were initially 
obtained from the bark and wood of Nyssacea 
Camptotheca accuminata and act by inhibiting 
topoisomerase I [20]. The taxanes and the 
camptothecins are presently approved for 
human use in various countries (Table 1).  
 
Table 1: Plant based anticancer agents in clinical 
practice.  
S.No. Compound Uses Status  
1. Vincristine Leukemia, lymphoma, 
breast, lung, pediatric 
solid cancers and 
others 
Phase 
III/IV 
2. Vinblastine Breast, lymphoma, 
germ-cell and renal 
cancer 
Phase 
III/IV 
 
3. Paclitaxel Ovary, breast, lung, 
bladder and head and 
neck cancer 
Phase 
III/IV 
 
4. Docetaxel Breast and lung cancer Phase III
5. Topotecan Ovarian, lung and 
pediatric cancer  
Phase 
II/III 
6. Irinotecan Colorectal and lung 
cancer  
Phase 
II/III 
Rohitukine the plant alkaloid, isolated from the 
leaves and stems of Dysoxylum binectariferum 
(Maliaceae) [21,22]. Synthetic flavone derived 
from rohitukine, Flavopiridol representing the 
first cyclin-dependent kinase inhibitor to enter 
the clinical trial [23]. The mechanism of action 
involves interfering with the phosphorylation of 
cyclin-dependent kinases and arrest cell-cycle 
progression at growth phase G1 or G2 [24,25]. 
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Homoharringtonine an alkaloid isolated from 
the Chinese tree Cephalotaxus harringtonia 
(Cephalotaxacea) [26]. The mechanism of action 
is the inhibition of protein synthesis and 
blocking cell-cycle progression [27]. It has 
shown efficacy against various leukemias [28]. 
A lung-cancer-specific antineoplastic agent 4-
Ipomeanol is isolated from the sweet potato 
Ipomoea batata (Convolvulaceae) [29]. The 
mechanism of action is converted into DNA-
binding metabolites upon metabolic activation 
by cytochrome P450 enzymes that are present in 
cells of the lung [30]. DNA topoisomerase I 
inhibitor β-lapachone, that induces cell-cycle 
delay at G1 or S (synthesis) phase before 
inducing either apoptotic or necrotic cell death 
in a variety of human carcinoma cells, including 
ovary, colon, lung, prostate and breast [31]. 
 
Beside this there are so many plants which are 
used in cancer; following enlist the plant which 
prevent and target for future studies as potential 
anticancer agent (Table 2): 
 
Table 2: Plants used as anti-cancer.  
S.No Plant Species Family Plant Part References
1. Salvia officinalis Labiatae  Leaves [32] 
2. Viscum album Loranthaceae Leaves [33] 
3. Combretum caffrum Combretaceae Bark [34] 
4. Melaleuca alternifolia Myrtaceae Leaves [35] 
5. Lavandula angustifolia Labiatae Leaves  [35] 
6. Aglaia foveolata Meliaceae Fruit [36] 
7. Maytenus serrata Celastraceae Seed [37] 
8. Tabebuia impetiginosa Bignoniaceae Stem bark and trunk wood [38,39] 
9. Tabebuia rosea Bignoniaceae Stem bark and trunk wood [38,39] 
10. Tabebuia serratifolia Bignoniaceae Stem bark and trunk wood [38,39] 
11. Dipteryx odorata   Fabaceae Seed [40] 
12. Thapsia garganica Apiaceae Fruit [41] 
13. Indigofera tinctoria Leguminosae Aerial part [42] 
14. Matricaria chamomilla Asteraceae Flower [43] 
15. Erythroxylum pervillei Erythroxylaceae Root [44] 
16. Broussonetia papyrifera Urticaceae Entire  [45] 
17. Cyclopia intermedia Fabaceae Leaves [46] 
18. Scutellariae radix, Scutellariae indica Labiatae Root  [47] 
19. Physalis philadelphica Solanaceae Seed [48] 
20. Dysoxylum binectariferum Meliaceae Stem bark  [49] 
21. Aristotelia chilensis Elaeocarpaceae Leaf and Stem [50] 
22. Cyathostemma argentium Annonaceae Root [51] 
23. Epimedium hunanense Berberidaceae Aerial parts [52] 
24. Croton urucurama Euphorbiacaeae Bark [53] 
25. Epilobium hirsutum Onagraceae Entire [54] 
26. Pleione bulbocodioides Orchidaceae Tuber [55] 
27. Cassia quinquangulata Caesalpiniaceae Root [56] 
28. Begonia glabra Begoniaceae Entire [57] 
29. Celastrus orbiculatus Celastraceae Entire [57] 
30. Croton draco Euphorbiacaeae Aerial parts [57] 
31. Smilax sieboldii Liliaceae Entire [58] 
32. Ximenia Americana Olacaceae Root [58] 
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33. Maytenus emarginata Celastraceae Entire [59] 
34. Sarcandra glabra Choranthaceae Entire [60] 
35. Salvia plebeian Labiatae Aerial  [61] 
36. Scutellaria barbata Labiatae Entire [62] 
37. Ocotea caparrapi Lauraceae  Essential oil [63] 
38. Caragana cuneata Leguminosae Leaf [64] 
39. Croton flavens Euphorbiacaeae Leaf [65] 
40. Euphorbia  heterophylla Euphorbiacaeae Stem [65] 
41. Echites vucatanensis Apocynaceae Latex [65] 
42. Thevetia ahouia Apocynaceae Leaf and Stem [65] 
43 Thevetia gaumeri Apocynaceae Leaf and Stem [65] 
44. Thevetia peruciana Apocynaceae Leaf and Stem [65] 
45. Euphorbia  ebracteolata Euphorbiacaeae Aerial parts [66] 
46. Dioscorea collettii Dioscoreaceae Rhizome [67] 
47. Juglans mandshurica Juglandaceae Root [68] 
48. Maackia tenuifolia Leguminosae Root [69] 
49 Juncus acutus Juncaceae Leaf [70] 
50. Hedyotis chrysotricha Rubiaceae Entire [71] 
51. Arisaema erubescens Araceae Root [72] 
52. Leptadenia hastate Asclepiadaceae Bark [73] 
53. Viscum calcaratum Loranthaceae Entire [74] 
54 Aphanamixis polystachya Meliaceae Stembark [75] 
55. Pratia nummularia Campanulaceae Entire [76] 
56. Aeonium arboretum Crassulaceae Leaf [77] 
57. Ocotea foetens Lauraceae Branchlets [77] 
58. Maytenus canariensis Celastraceae Fruit juice [78] 
59. Sedum alboroseum Crassulaceae Entire [79] 
60. Euphorbia micractina Euphorbiacaeae Entire [80] 
61. Euphorbia prolifera Euphorbiacaeae Latex [81] 
62. Scirpus holoschoenus Cyperaceae Inflorescence [82] 
63. Dillenia suffruticosa Dilleniaceae Fruit [83] 
64 Hypoxis rooperii Hypoxiaceae Tuber [84] 
65. Inula linariaefolia Compositae Flowers [85] 
66. Ziziphus mauritiana Rhamnaceae Stem bark and Fruit [86] 
67. Adiantum macrophyllum Pteridaceae Entire [87] 
68. Thalictrum fabri Ranunculaceae Root [88] 
69. Scutellaria indica Labiatae Root [89] 
70. Hypericum japonicum Guttiferae Entire [90] 
71. Cyathea fauriei Cyatheaceae Shoot [91] 
72. Fissistigma oldhamii  Annonaceae Stem [92] 
73. Monnina obtusifolia Polygalaceae Aerial parts [93] 
74. Coriolus versicolor Polyporaceae Fruitbody [94] 
75. Melastoma malabathricum Melatomataceae Flower [95] 
76. Carapa guianensis Meliaceae Seed oil [96] 
77. Swietenia humilis Meliaceae Seed [97] 
78. Ficus pretoiae Moraceae Sap [98] 
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79. Croton lechleri Euphorbiacaeae Latex [99] 
80. Aster amellus Compositae Entire [100] 
81. Crassocephalum bojeri Compositae Entire [101] 
82. Echinops grijisii Compositae Root [101] 
83. Adenium obesum Apocynaceae Leaf  [102] 
84. Ipomea batata Convolvulaceae  Rhizome [103] 
85. Uncaria tomentosa Rubiaceae Bark [104] 
86. Plantago asiatica Plantaginaceae Leaf [105] 
87. Phymatosorus diversifolium Polydiaceae Root [105] 
88. Rabdosia rubescens Labiatae Leaf [106] 
89. Salvia chinensis Labiatae Entire [107] 
90. Ganoderma lucidum Ganodermataceae Fruitbody [108] 
91. Euphorbia kansui Euphorbiacaeae Root [109] 
92. Echinops latifolius Compositae Root [110] 
93. Euphorbia marginata Euphorbiacaeae Entire [111] 
94. Ligustrum lucidum Oleaceae Seed [112] 
95. Phytolacca esculenta Phytolaccaceae Root [113] 
96. Pinus parviflora Pinaceae Strobilus [114] 
97. Dysosma pleiantha Berberidaceae Root [115] 
98. Alnus japonica Betulaceae  Wood [116] 
99. Ruellia tuberose Acanthaceae Bark [117] 
100. Acacia xanthophloea Leguminosae Fruit [118] 
101. Lannea stuhlmannii Anacardiaceae Root [118] 
102. Maytenus obscura Celastraceae Leaf [118] 
103. Plicosepalus sagittifolius Loranthaceae Branches [118] 
104. Piper latifolium Piperaceae Leaf [119] 
105. Morinda citrifolia Rubiaceae Root [119] 
106. Knema tenuinervia Myristicaceae Stembark [120] 
107. Deeringia amaranthoides Amaranthaceae Fruit [121] 
108. Cynanchum hancoekianum  Asclepiadaceae Entire [122] 
109. Azadirachta indica Meliaceae Leaf [123] 
110. Virola bicuhyba Myristicaceae Seed [124] 
111. Sempervivum armenum Crassulaceae Leaf [125] 
112. Sempervivum arvense Crassulaceae Leaf [125] 
113. Hippophae salicifolia  Elaeagnaceae Fruit [126] 
114. Hypoxis nyasica Hypoxiaceae Rhizome [127] 
115. Astragalus membranaceus Leguminosae Root [128] 
116. Maytenus macrocarpa Celastraceae Stembark [129] 
117. Cephalotaxus Harrington Cephlotaxaceae Entire  [130] 
 
Dietary source of anti cancer agents: 
Natural dietary agents including fruits, 
vegetables, and spices have drawn a great deal 
of attention from both the scientific community 
and the general public owing to their 
demonstrated ability to suppress cancers. Recent 
studies suggest that the consumption of food 
rich in fruits, vegetables and spices have a lower 
incidence of cancers (stomach, esophagus, lung, 
oral cavity and pharynx, endometrium, pancreas 
and colon) [131-133].  
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Dietary agents consist of a wide variety of 
biologically active components that are 
responsible for the anti-cancer effects like 
curcumin, genistein, resveratrol, diallyl sulfide, 
S-allyl cysteine, allicin, lycopene, capsaicin, 
diosgenin, gingerol, ellagic acid, ursolic acid, 
silymarin, anethol, catechins, eugenol, 
isoeugenol, dithiolthiones, isothiocyanates, 
indole-3-carbinol, isoflavones, saponins, 
phytosterols, inositol hexaphosphate, Vitamin 
C, D-limonene, lutein, folic acid, beta carotene, 
selenium, Vitamin E and flavonoids (Table 3). 
Many of which have been used in traditional 
medicines for thousands of years. These dietary 
agents are believed to suppress the 
inflammatory processes that lead to 
transformation, hyperproliferation, and initiation 
of carcinogenesis. Their inhibitory influences 
may ultimately suppress the final steps of 
carcinogenesis i.e angiogenesis and metastasis 
[134]. 
 
Table 3: Dietary sources as anticancer agent. 
S. No. Botanical Name Source Compound Reference 
1 Carica papaya, Family- Caricaceae Berries β-Cryptoxanthin [135] 
2 Glycyrrhiza glabra; Glycyrrhiza radix; 
Glycyrrhiza uralensis, Family- Leguminosae 
Licorice root Glycyrrhizin [136] 
3 Cannabis sativa, Family- Cannabiaceae Hemp  Cannabinol [137] 
4 Rosmarinus officinalis, Family- Lamiaceae Rosemary Carnosol [138] 
5 Pueraria lobata radix, Family- Fabaceae  Genistein [139] 
6 Glycine max, Family- Fabaceae Soybeans Genistein [139] 
7 Prunus armeniaca, Family- Rosaceae Apricots Carotenoids [140] 
8 Zingiber officinale, Family- Zingiberaceae Tuber Gingerol [141] 
9 Lycopersicon esculentum, Family- Solanaceae Tomato Lycopene, Lutein, 
Kaempferol  
[141] 
10 Piper nigrum; Piper longum, Family- Piperaceae Black pepper Purpurogallin; 
Piperine 
[142] 
11 Ocimum sanctum, Family-Lamiaceae Basil Ursolic acid [143] 
12 Betula alba, Family- Betulaceae Birch tree Betulinic acid [144] 
13 Crocus sativus, Family- Iridaceae Saffron Carotenoids [146] 
14 Silymarin marianum, Family- Asteraceae Milk thistle Silymarin [147] 
15 Capsaicum annum; Capsaicum frutens, Family- 
Solanaceae   
Red chilli Capsaicinoids, 
Capsaicin 
[148] 
16 Camellia sinensis, Family- Theaceae Green and 
black teas 
Catechin and 
theaflavins 
[149] 
17 Vitis vinifera, Family- Vitaceae Grapes Resveratrol  [150] 
18 Daucus carota sativus, Family- 
Apiaceae/umbelliferae   
Carrot β-Carotene [151] 
19 Tabebuia avellanedae, Family- Bignoniaceae Lapacha tree Lapachone [31] 
20 Citrus aurantium, Family- Rutaceae Orange Hesperidin [152] 
21 Prunus dulcis, Family- Rosaceae Almond Morin [153,154] 
22 Aloe arborescens, Family- Asphodelaceae Aloe vera Emodin [155] 
23 Opium poppy, Family- Paparveraceae Poppy Morphine and its 
analogues 
[157] 
24 Curcurbita moschata, Family-Cucurbitaceae  Pumpkin β-Carotene [158] 
25 Azadirachata indica, Family- Meliaceae Neem Polyphenolics [159] 
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Marines as source of anti-cancer 
agents: 
Marine organisms are a rich source for natural 
products [160]. In recent time, advancement in 
deep-sea collection and aqua culture technology 
gives significant number of compounds derived 
from marine organisms entering preclinical and 
early clinical evaluation as potential anticancer 
agent [161,162]. Overall, more than 3000 new 
substances have been identified from marine 
organisms that demonstrate the great potential 
as a source of novel chemical classes [163]. 
Marine belongs to very diverse structural classes 
including polyketides, terpenes, steroids and 
peptides. The organisms yielding these bioactive 
marine compounds include invertebrate animals, 
algae, fungi and bacteria [164].  
 
The first anticancer product didemnin B, a 
cyclic depsipeptide isolated from the tunicate 
Trididemnum solidum from marine source enter 
in clinical trials. Preliminary results showed a 
partial activity against non-Hodgkin’s 
lymphoma [165]. It can inhibit protein synthesis 
and arrest G1 phase of cell-cycle. Another 
depsipeptide Aplidine appear to be more active 
as comparison with didemninB in preclinical 
trial and does not produce life-threatening 
neuromuscular toxicity. Preclinical data indicate 
that aplidine is active against several tumors 
through blockade of cell-cycle progression at 
G1 phase [166]. There are number of 
ecteinascidins have been isolated from the 
marine source tunicate Ecteinascidia turbinata. 
One of these ecteinascidins (ET-743) was 
selected for clinical trials and antitumor effects 
have been observed in phase I studies [167]. ET-
743 is a tetrahydroisoquinilone alkaloid and 
they acts by selective alkylation of guanine 
residues in the DNA minor groove [168] and 
also interacts with nuclear proteins [169]. In 
Europe and the United States ET-743 is 
currently in phase II clinical trials [167]. The 
dolastatins are a class of peptides obtained from 
the Indian Ocean, Dolabella auricularia. These 
peptides have cytotoxic activity and now a day, 
dolastatin10 and dolastatin15 of this class have 
received the greatest clinical interest. 
Dolastatin10 has entered in Phase I and Phase II 
clinical trials, after showing significant 
antitumor activity in preclinical models [170]. 
Its mechanism of action involves inhibition of 
microtubule assembly ultimately result in cell-
cycle arrest in metaphase [171,172]. The 
bryostatins, 20 macrocyclic lactones isolated 
from Bugula neritina and other marine bryozoa. 
These macrocyclic compounds have shown 
significant activity against lymphocytic 
leukemia cell line [173]. Bryostatin1 has 
recently entered phase II clinical trials for the 
treatment of melanoma, non-Hodgkin’s 
lymphoma, renal cancer and colorectal cancer 
[174-176] and continues to be evaluated in 
phase I clinical trials. Bryostatin1 has been 
found to promote the normal growth of bone 
marrow progenitor cells, to provide in vivo 
protection against normally lethal doses of 
ionizing radiation and to serve as an immune 
stimulant, enhancing the normal production of 
interleukin2 and interferons [177].  
 
Beside this there are the number of compounds 
isolated from marine as potential anti-cancer 
agents included in Table 4 [178,179]. 
 
Microorganisms as source of anti-
cancer agents: 
Antitumor antibiotics are among the most 
important cancer chemotherapeutic agents, and 
include members of the anthracycline, 
bleomycin, actinomycin, mitomycin and 
aureolic acid families [6]. Clinically useful 
agents from these above families are the 
daunomycin and related agents like doxorubicin, 
idarubicin and epirubicin; the peptolides 
(exemplified by dactinomycin), the mitosanes 
(such as mitomycin C) and the glycosylated 
anthracenone mithramycin. The anthracyclines 
are among the most used antitumor antibiotics 
in the clinic and exert antitumor activity mainly 
by inhibiting topoisomerase II [180,181]. 
Table 4: Marine derived potential anticancer agent. 
S.No. Compound Organism Chemistry Mechanism of action 
1. Aaptamine Sponge Alkaloid Induction of p21 and G2/M cell cycle 
arrest 
2. Cortistatin A Sponge Alkaloid Selective inhibiton of angiogensis 
3. Aplidine Ascidian  Depsipeptide Oxidation and inactivation of low 
molecular weight-protein tyrosine 
phosphatase activity 
4. Bastadine 6 Sponge Alkaloid Inhibition of angiogenesis in vitro and 
in vivo involves apoptosis 
5. Fucoxanthinol Ascidian Carotenoid Induction of apoptosis  
6. Lamellarin D  Mollusk Alkaloid ErbB3 protein and PI3K- Akt pathway 
involved in necrosis induction 
7. Clavulone II Soft coral Prostanoid G1 cell cycle arrest and apoptosis 
8. Geodiamolides Sponge Peptide Disorganization of actin filaments 
9. Ircinin-1 Sponge Sesterterpene G1 phase inhibition and apoptosis 
induction 
10. Laxaphycins A and 
B 
Bacterium  Cyclic peptides Increased polyploidy by putative 
topoisomerase II alterations 
11. Leptosins C and F  Fungus Alkaloid DNA topoisomerase I and II inhibition 
and apoptosis induction 
12. Onnamide A Sponge Polyketide  Protein synthesis inhibition 
13. Philinopside A Sea cucumber Saponin Inhibition of angiogenesis and 
receptor tyrosine kinases  
14. Variolin B Sponge  Alkaloid Inhibition of cyclin-dependent kinases 
and apoptosis induction  
15. Aplidine Ascidian Depsipeptide Induction of apoptosis with 
concomitant G1 arrest and G2 
blockage 
16. Ascididemin Ascidian Alkaloid Direct iminoquinone reduction and 
reactive oxygen species generation  
17. Cammbrescidin 
800 
Sponge Alkaloid Induction of eythroid differentiation 
and cell cycle arrest 
18. Dideoxypetrosynol 
A 
Sponge Fatty acid Induction of apoptosis via 
mitochondrial signaling pathway 
19. Dolastatin 10 Mollusc Peptide Binds to amino-terminal peptide of β-
tubulin containing cysteine 
20. Girolline Sponge Alkaloid Induction of G2/M cell cycle arrest 
and p53 proteasome recruitment 
21. Halichondrin B 
analogues 
Sponge Macrolide 
derivative 
Induction of mitotic blockage and 
apoptosis 
22. Lissoclinolide Ascidian Fatty acid G2/M cell cycle arrest 
23. Neoamphimedine Sponge  Alkaloid Induction of topoisomerase II α-
mediated catenation of DNA  
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24. Psammaplin A Sponge Alkaloid Inhibition of aminopeptidase N and 
suppression of angiogenesis in vitro 
25. Alkylpyridinium Sponge Alkaloid Induction of apoptosis and reduced 
cell adhesion 
26. Aeroplysinin Sponge Alkaloid Induction of apoptosis on proliferating 
endothelial cells 
27. Bryostatin-1 Bryozoan Macrolide Potentiation of ara-C induced 
apoptosis by PKC-dependent release 
of TNF-α 
28. Cephaiostatin Worm Steroid Apoptosis and increased mitochondrial 
matrix density 
29. Chondropsin A Sponge Macrolide In Vitro inhibition of V-ATPase 
enzyme 
30. Dehydrothrysiferol Alga Triterpene Enhanced apoptosis induction in 
estrogen receptor negative breast 
cancer cells 
31. Diazonamide-A Ascidian Peptide Disruption of mitosis and cellular 
microtubules with inhibition of GTP 
hydrolysis   
32. Dictyostatin Sponge Polyketide Induction of tubulin polymerization  
33. Dolastatin 11 Mollusc Peptide F-actin stabilization by connection 
between two long-pitch strands 
34. Ecteinascidin- 743 Ascidian Isoquinoline 
alkaloid 
Telomere dysfunction increases 
susceptibility to ET-743 
35. GA3 
polysaccharide  
Alga  
 
Polysaccharide Inhibition of topoisomerase I and II 
36. Hemiasterlin 
analogue 
Sponge Tripeptide Induction of microtubule 
depolymerisation 
37. Kahalalide F Mollusc Depsipeptide Potent cytotoxicity and induction of 
necrosis 
38. Lamellarin D Mollusc Alkaloid Potent inhibition of topoisomerase I 
39. omega-3 fatty 
acids 
Fish Fatty acid           -- 
 Many pharmaceutical agents have been 
discovered by screening natural products from a 
wide range of microorganisms. Rapamycin and 
its analogs are products of Streptomyces 
hygroscopicus have potent immunosuppressive 
activity. They inhibit signaling pathways 
required for T-cell activation and proliferation. 
Rapamycin blocks progression of the cell cycle 
at middle-to-late G1 phase in T cells and B 
cells, and osteosarcoma and rhabdomyosarcoma 
cell lines, among others [182]. Geldanamycin is 
a benzoquinone ansamycin natural fermentation 
product and inhibits heat-shock protein HSP 90 
[183].  
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Table 5: Microorganism derived anti-cancer agents. 
 
Wortmannin is a product of the fungus 
Talaromyces wortmanni and inhibits signal 
transduction pathways by forming a covalent 
complex with an active-site residue of 
phosphoinositide 3 kinase (PI3K), inhibiting 
PI3K activity [184] (Table 5). Thus, toxins that 
originally evolved to kill competing 
micoorganisms can have a variety of 
physiological effects in animals. In many cases, 
the targets of these compounds are components 
of signal transduction cascades that are 
conserved in many species, and that have been 
considered novel targets for anticancer drug 
discovery [185]. 
 
Conclusion:  
Natural products have been a prime source for 
the treatment of many forms of cancer, many of 
which are consumed daily with the diet. They 
provide significant protection against various 
cancers and many other diseases. The 
antioxidant medicinal plants and their products 
prevent from the cancer and other diseases by 
protecting cells from damage. Thus, consuming 
a diet rich in antioxidant fruits, vegetables, 
herbs etc. will provide health-protective effects. 
Microbes and marine organisms also have been 
offering the great role in the prevention and 
treatment of cancer. All the natural products 
discussed in this review exhibit anticancer 
activities. Natural products offer a great 
opportunity to evaluate not only totally new 
chemical classes of anticancer agents, but also 
novel and potentially relevant mechanisms of 
action. 
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